Sara Tomassini

• MBBS
• PARP and RAD51 protein expression as biomarkers of homologous recombination status in ovarian cancer

The development of predictive tests indicating response to treatment is a major focus of cancer research, as it allows the advancement of so-called stratified medicine, which attempts to identify effective treatments based on an individual’s specific cancer. In this project we carried out some preliminary work to examine whether PARP1 and RAD51 protein expression, is a reliable marker to separate ovarian cancers into one of two groups which are known to respond differently to chemotherapy. This was achieved through immunohistochemical (IHC) labelling of TMAs and subsequent scoring using the Aperio Scanscope software.

Funding source: INSPIRE